Ultragenyx Pharmaceutical Inc. (RARE) Stock Price

RAREStock

$26.46−13.63%52W

Market Cap$2.61B

P/E—

PEG Ratio—

Div yield—

Beta0.27

RARE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)14.52%

Price vs S&P 500 (4W)-4.05%

VGM Score54.71

Book Value / Share (Quarterly)$0.10

P/TBV (Annual)50.46x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)22.81%

Cash Flow / Share (Quarterly)$-5.01

Price vs S&P 500 (YTD)-0.13%

Gross Margin (TTM)83.11%

Net Profit Margin (TTM)-81.73%

EPS (TTM)$-5.84

10-Day Avg Trading Volume1.96M

EPS Excl Extra (TTM)$-5.84

Revenue Growth (5Y)19.95%

EPS (Annual)$-5.83

ROI (Annual)-50.60%

Gross Margin (Annual)83.80%

Net Profit Margin (5Y Avg)-130.13%

Cash / Share (Quarterly)$2.96

Revenue Growth QoQ (YoY)28.53%

ROA (Last FY)-37.53%

Revenue Growth TTM (YoY)17.50%

EBITD / Share (TTM)$-4.92

ROE (5Y Avg)-141.85%

Operating Margin (TTM)-73.67%

Cash Flow / Share (Annual)$-5.04

P/B Ratio283.96x

P/B Ratio (Quarterly)316.50x

Net Income / Employee (Annual)$-419,400

EV / Revenue (TTM)5.04x

Net Interest Coverage (TTM)-14.43x

ROA (TTM)-44.37%

EPS Incl Extra (Annual)$-5.83

Current Ratio (Annual)2.48x

Quick Ratio (Quarterly)1.43x

3-Month Avg Trading Volume2.11M

52-Week Price Return-13.63%

Revenue / Employee (TTM)$522,900

Tangible BV / Share (Quarterly)$0.83

P/S Ratio (Annual)3.86x

Asset Turnover (Annual)0.44x

52-Week High$39.89

Operating Margin (5Y Avg)-118.69%

EPS Excl Extra (Annual)$-5.83

CapEx CAGR (5Y)-13.72%

Tangible BV CAGR (5Y)-31.88%

26-Week Price Return25.77%

Quick Ratio (Annual)2.22x

13-Week Price Return8.48%

Total Debt / Equity (Annual)3.41x

Current Ratio (Quarterly)1.73x

Enterprise Value$3.62B

Revenue / Share Growth (5Y)8.90%

Asset Turnover (TTM)0.54x

Book Value / Share Growth (5Y)-24.58%

Revenue / Employee (Annual)$490,900

Inventory Turnover (Annual)2.25x

Pretax Margin (Annual)-84.84%

Cash / Share (Annual)$7.04

3-Month Return Std Dev52.63%

Gross Margin (5Y Avg)89.47%

Net Income / Employee (TTM)$-427,400

ROE (Last FY)-222.95%

Net Interest Coverage (Annual)-10.08x

EPS Basic Excl Extra (Annual)$-5.83

Receivables Turnover (TTM)4.42x

Total Debt / Equity (Quarterly)90.54x

EPS Incl Extra (TTM)$-5.84

Receivables Turnover (Annual)4.81x

ROI (TTM)-58.61%

P/S Ratio (TTM)3.63x

Pretax Margin (5Y Avg)-129.67%

Revenue / Share (Annual)$6.83

Tangible BV / Share (Annual)$0.83

Price vs S&P 500 (52W)-31.94%

Year-to-Date Return11.83%

5-Day Price Return0.90%

EPS Normalized (Annual)$-5.83

ROA (5Y Avg)-38.33%

Net Profit Margin (Annual)-85.44%

Month-to-Date Return3.25%

Cash Flow / Share (TTM)$-8.66

EBITD / Share (Annual)$-5.34

Operating Margin (Annual)-79.49%

LT Debt / Equity (Annual)3.21x

ROI (5Y Avg)-73.69%

LT Debt / Equity (Quarterly)83.39x

EPS Basic Excl Extra (TTM)$-5.84

P/TBV (Quarterly)50.46x

P/B Ratio (Annual)15.22x

Inventory Turnover (TTM)2.30x

Pretax Margin (TTM)-81.21%

Book Value / Share (Annual)$2.76

Price vs S&P 500 (13W)5.68%

Beta0.27x

Revenue / Share (TTM)$7.04

ROE (TTM)-414.17%

52-Week Low$18.29

vGradeD

gGradeB

mGradeC

vgmGradeC

RARE Earnings Surprise History

Q2 25-1.17est. -1.32

Q3 25-1.81est. -1.21

Q4 25-1.29est. -1.17

Q1 26-1.54est. -1.46

Q2 26-0.90est. -1.00

RARE Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.19

4.20

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
RAREUltragenyx Pharmaceutical Inc.	D	B	C	$26.46
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical is a biopharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases. The company's marketed portfolio includes Crysvita (for X-linked hypophosphatemia) and Mepsevii (for Mucopolysaccharidosis VII), with additional therapies in development. Operating globally across North America, Europe, Asia-Pacific, and other regions, Ultragenyx generates the majority of its revenue from North America.